AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20473257 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower doses for persistent ARDS
Number of subjects: 0
Study 17703218 — intervention group
Group type: EXPERIMENTAL
Intervention: Prelox (combination of L‐arginine aspartate and Pycnogenol)
Number of subjects: 50
Study 17703218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 15877558 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin troche supplementation before every meal for 4 weeks
Number of subjects: 64
Study 15877558 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin troche supplementation
Number of subjects: 64
Study 15877558 — intervention group
Group type: COMPARATOR
Intervention: Placebo troche
Number of subjects: 64
Study 12422064 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg opipramol
Number of subjects: 72
Study 12422064 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg opipramol
Number of subjects: 72
Study 12422064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 10325662 — intervention group
Group type: EXPERIMENTAL
Intervention: Active NSAID (Piroxicam 20 mg)
Number of subjects: 473
Study 10325662 — intervention group
Group type: EXPERIMENTAL
Intervention: Active NSAID (Meloxicam 15 mg)
Number of subjects: 473
Study 10325662 — intervention group
Group type: EXPERIMENTAL
Intervention: Active NSAID (Meloxicam 22.5 mg)
Number of subjects: 473
Study 10325662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 473
Study 10325662 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam 22.5 mg
Number of subjects: 473
Study 10325662 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam 15 mg
Number of subjects: 473
Study 10325662 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 20 mg
Number of subjects: 473
Study 8952580 — intervention group
Group type: EXPERIMENTAL
Intervention: Apneic subjects
Number of subjects: 0
Study 8952580 — intervention group
Group type: COMPARATOR
Intervention: Nonapneic subjects
Number of subjects: 0
Study 8952580 — intervention group
Group type: EXPERIMENTAL
Intervention: Both apneic and nonapneic subjects during stages 3 and 4 of non-REM sleep
Number of subjects: 0
Study 8952580 — intervention group
Group type: EXPERIMENTAL
Intervention: Apneic subjects with ischemic heart disease
Number of subjects: 0
Study 1770156 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.50 mg for 1, 6, and 12 nights
Number of subjects: 11
Study 1770156 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 nights
Number of subjects: 11
Study 1770156 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.50 mg for 12 nights
Number of subjects: 11
Study 1770156 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.50 mg for 1 and 6 nights
Number of subjects: 11
Study 7196801 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin, vincristine, and 5-FU (AVF)
Number of subjects: 61
Study 7196801 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (CTX)
Number of subjects: 61
Study 7196801 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin, vincristine, and 5-FU (AVF) after failing CTX
Number of subjects: 61
Study 7196801 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CTX) after failing AVF
Number of subjects: 61
Study 30329163 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminolaevulinic acid nanoemulsion (BF-200 ALA)
Number of subjects: 69
Study 30329163 — intervention group
Group type: COMPARATOR
Intervention: methyl-5-aminolaevulinate (MAL)
Number of subjects: 69
Study 30329163 — intervention group
Group type: COMPARATOR
Intervention: methyl-5-aminolaevinate (MAL)
Number of subjects: 69
Study 29914494 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy-led exercise and behavioural support intervention
Number of subjects: 350
Study 29914494 — intervention group
Group type: COMPARATOR
Intervention: Best practice usual care
Number of subjects: 350
Study 27964756 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) 2 g
Number of subjects: 185
Study 27964756 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of RF, anti-CCP, and high serum IgG
Number of subjects: 185
Study 24682844 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0
Study 21761707 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 86
Study 21761707 — intervention group
Group type: COMPARATOR
Intervention: Focused ultrasound
Number of subjects: 86
Study 20025635 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg isoflavones (60 mg of genistein)
Number of subjects: 180
Study 20025635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 18162021 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (20-30 mg/day)
Number of subjects: 1294
Study 18162021 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (5-10 mg/day)
Number of subjects: 1294
Study 15238035 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype model
Number of subjects: 0
Study 15238035 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemplar model with response-scaling mechanism
Number of subjects: 0
Study 15238035 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype model and exemplar model with response-scaling mechanism
Number of subjects: 0
Study 11546945 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil 120 mg once daily
Number of subjects: 505
Study 11546945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 505
Study 9128034 — intervention group
Group type: EXPERIMENTAL
Intervention: Low flow anesthesia (300 ml.min‐1 of oxygen, 300 ml.min‐1 of nitrous oxide or 400 ml.min‐1 of oxygen, 200 ml.min‐1 of nitrous oxide)
Number of subjects: 39
Study 9128034 — intervention group
Group type: COMPARATOR
Intervention: High flow anesthesia (2 l.min‐1 of oxygen, 4 l.min‐1 of nitrous oxide)
Number of subjects: 39
Study 9128034 — intervention group
Group type: EXPERIMENTAL
Intervention: Low flow anesthesia
Number of subjects: 39
Study 9128034 — intervention group
Group type: COMPARATOR
Intervention: High flow anesthesia
Number of subjects: 39
Study 8179457 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin protocol (5000 U bolus, followed by 1680 U/h or 1240 U/h)
Number of subjects: 68
Study 8179457 — intervention group
Group type: COMPARATOR
Intervention: Non-protocol physician management
Number of subjects: 68
Study 3067749 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily relaxation technique for 3 weeks
Number of subjects: 24
Study 31550904 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT‐Open (acceptance, defusion components)
Number of subjects: 55
Study 31550904 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT‐Engaged (values, committed action)
Number of subjects: 55
Study 31550904 — intervention group
Group type: COMPARATOR
Intervention: ACT‐Combined (acceptance, defusion, values, committed action)
Number of subjects: 55
Study 30356245 — intervention group
Group type: EXPERIMENTAL
Intervention: School corporal punishment
Number of subjects: 1752
Study 30356245 — intervention group
Group type: EXPERIMENTAL
Intervention: Home corporal punishment
Number of subjects: 1752
Study 30356245 — intervention group
Group type: EXPERIMENTAL
Intervention: Food insecurity
Number of subjects: 1752
Study 30356245 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer violence
Number of subjects: 1752
Study 30356245 — intervention group
Group type: EXPERIMENTAL
Intervention: School performance and attendance
Number of subjects: 1752
Study 27554636 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 18
Study 27554636 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant 20 mg
Number of subjects: 18
Study 27554636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 24857397 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine supplementation (1‐3μg/kg/day) for 120 days
Number of subjects: 28
Study 24857397 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 120 days
Number of subjects: 28
Study 22348983 — intervention group
Group type: EXPERIMENTAL
Intervention: lasofoxifene 0.5mg/d
Number of subjects: 1126
Study 22348983 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1126
Study 20008155 — intervention group
Group type: EXPERIMENTAL
Intervention: Two antismoking ads
Number of subjects: 84
Study 20008155 — intervention group
Group type: COMPARATOR
Intervention: Two prosocial ads
Number of subjects: 84
Study 20008155 — intervention group
Group type: COMPARATOR
Intervention: Smoking portrayal in the movie
Number of subjects: 84
Study 20008155 — intervention group
Group type: COMPARATOR
Intervention: No smoking portrayal in the movie
Number of subjects: 84
Study 18724648 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretinoin microsphere gel 0.04% applied once nightly for 12 weeks
Number of subjects: 629
Study 18724648 — intervention group
Group type: COMPARATOR
Intervention: Vehicle gel (placebo)
Number of subjects: 629
Study 18724648 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretinoin microsphere gel 0.04%
Number of subjects: 629
Study 16215369 — intervention group
Group type: COMPARATOR
Intervention: Standard care (placebo arms of two trials)
Number of subjects: 1036
Study 12929008 — intervention group
Group type: EXPERIMENTAL
Intervention: Harvesting from the ventral iliac crest
Number of subjects: 113
Study 12929008 — intervention group
Group type: COMPARATOR
Intervention: Harvesting from the dorsal iliac crest
Number of subjects: 113
Study 10563706 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent therapy with zidovudine, lamivudine, loviride and zalcitabine (T4)
Number of subjects: 100
Study 10563706 — intervention group
Group type: COMPARATOR
Intervention: Cyclical therapy with the same four drugs (C4)
Number of subjects: 100
Study 10563706 — intervention group
Group type: COMPARATOR
Intervention: Concurrent zidovudine and lamivudine (T2)
Number of subjects: 100
Study 8688345 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 16 mg suppository once daily
Number of subjects: 20
Study 8688345 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 8 mg tablets twice daily
Number of subjects: 20
Study 1677822 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium (group A)
Number of subjects: 64
Study 1677822 — intervention group
Group type: EXPERIMENTAL
Intervention: Metocurine plus pancuronium (group MP)
Number of subjects: 64
Study 1677822 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium (group V)
Number of subjects: 64
Study 6217921 — intervention group
Group type: EXPERIMENTAL
Intervention: sulfinpyrazone
Number of subjects: 48
Study 6217921 — intervention group
Group type: EXPERIMENTAL
Intervention: aspirin/dipyridamole
Number of subjects: 48
Study 6217921 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 48
Study 30007039 — intervention group
Group type: EXPERIMENTAL
Intervention: PRF alone
Number of subjects: 40
Study 30007039 — intervention group
Group type: EXPERIMENTAL
Intervention: PRF + 1% Alendronate (ALN) gel
Number of subjects: 40
Study 30201456 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper limb ischemic postconditioning (LIPostC)
Number of subjects: 60
Study 30201456 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure (control)
Number of subjects: 60
Study 26787231 — intervention group
Group type: EXPERIMENTAL
Intervention: High neutrophil-to-lymphocyte ratio (NLR) defined as >3.0
Number of subjects: 908
Study 26787231 — intervention group
Group type: COMPARATOR
Intervention: Low neutrophil-to-lymphocyte ratio (NLR)
Number of subjects: 908
Study 26787231 — intervention group
Group type: EXPERIMENTAL
Intervention: High neutrophil-to-lymphocyte ratio (NLR)
Number of subjects: 908
Study 25169796 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal PR interval group (n=199)
Number of subjects: 403
Study 25169796 — intervention group
Group type: COMPARATOR
Intervention: Prolonged PR interval group (n=204)
Number of subjects: 403
Study 22166897 — intervention group
Group type: EXPERIMENTAL
Intervention: Rose hip powder drink
Number of subjects: 31
Study 22166897 — intervention group
Group type: COMPARATOR
Intervention: Control drink
Number of subjects: 31
Study 19384775 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic contour tonometry (DCT)
Number of subjects: 33
Study 19384775 — intervention group
Group type: COMPARATOR
Intervention: Goldmann applanation tonometry (GAT)
Number of subjects: 33
Study 17931465 — intervention group
Group type: EXPERIMENTAL
Intervention: Invariant paradigm with pairs of 2-digit numbers governed by a rule
Number of subjects: 0
Study 17931465 — intervention group
Group type: EXPERIMENTAL
Intervention: Invariant paradigm with controlled biases in Experiments 2 and 3
Number of subjects: 0
Study 15015149 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide
Number of subjects: 0
Study 15015149 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0
Study 15015149 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 11432031 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial prophylaxis for orthopaedic surgery
Number of subjects: 0
Study 9645977 — intervention group
Group type: EXPERIMENTAL
Intervention: Best medical care plus carotid endarterectomy (CE)
Number of subjects: 1996
Study 9645977 — intervention group
Group type: COMPARATOR
Intervention: Best medical care alone
Number of subjects: 1996
Study 9645977 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1996
Study 7916914 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine sulfate 30 mg
Number of subjects: 0
Study 7916914 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine sulfate 15 mg
Number of subjects: 0
Study 7916914 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.9% NaCl)
Number of subjects: 0
Study 2811648 — intervention group
Group type: EXPERIMENTAL
Intervention: Single drug for movement disorder
Number of subjects: 2
Study 2811648 — intervention group
Group type: COMPARATOR
Intervention: Potentially useful but toxic drug
Number of subjects: 2
Study 1244405 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical-mental practice
Number of subjects: 140
Study 1244405 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical practice
Number of subjects: 140
Study 1244405 — intervention group
Group type: EXPERIMENTAL
Intervention: One-half physical practice
Number of subjects: 140
Study 1244405 — intervention group
Group type: COMPARATOR
Intervention: Control group (no practice)
Number of subjects: 140
Study 29208758 — intervention group
Group type: EXPERIMENTAL
Intervention: Impedance-based respiratory volume monitor (RVM)
Number of subjects: 65
Study 29208758 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study 26597211 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use (475 patients, 43.5% of the population)
Number of subjects: 1093
Study 26597211 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-statin users)
Number of subjects: 1093
Study 25068456 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight stigma exposure
Number of subjects: 45
Study 25068456 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived stress mediation
Number of subjects: 45
Study 22409880 — intervention group
Group type: EXPERIMENTAL
Intervention: GW274150 60 mg
Number of subjects: 50
Study 22409880 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 7.5 mg
Number of subjects: 50
Study 22409880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 20858230 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on infectious diseases (A)
Number of subjects: 0
Study 20858230 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of rapid diagnostic tests (RDTs) (B)
Number of subjects: 0
Study 20858230 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of training and RDTs (AB)
Number of subjects: 0
Study 20858230 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 0
Study 19039291 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based video exercise program (26 minutes, three times per week for five months)
Number of subjects: 61
Study 19039291 — intervention group
Group type: COMPARATOR
Intervention: Control group (bi-weekly telephone call, no exercise intervention)
Number of subjects: 61
Study 17575754 — intervention group
Group type: EXPERIMENTAL
Intervention: Right paracolic adhesiolysis
Number of subjects: 25
Study 17575754 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 25
Study 17575754 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative laparoscopy (for all subjects)
Number of subjects: 25
Study 14666757 — intervention group
Group type: EXPERIMENTAL
Intervention: TCM treatment based on syndrome differentiation of TCM
Number of subjects: 82
Study 14666757 — intervention group
Group type: COMPARATOR
Intervention: Conventional method of western medicine (Control)
Number of subjects: 82
Study 11011339 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 3831
Study 11011339 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 3831
Study 11011339 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH) - Subtherapeutic
Number of subjects: 3831
Study 11011339 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH) - Therapeutic
Number of subjects: 3831
Study 11011339 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH) - Supratherapeutic
Number of subjects: 3831
Study 8865767 — intervention group
Group type: EXPERIMENTAL
Intervention: Online tutorial group
Number of subjects: 56
Study 8865767 — intervention group
Group type: EXPERIMENTAL
Intervention: Text guide group
Number of subjects: 56
Study 8865767 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial guide group
Number of subjects: 56
Study 8865767 — intervention group
Group type: COMPARATOR
Intervention: Description group
Number of subjects: 56
Study 1818759 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon calcitonin (100 IU) daily injections
Number of subjects: 56
Study 1818759 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 56
Study 6827742 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer data base
Number of subjects: 1016
Study 6827742 — intervention group
Group type: EXPERIMENTAL
Intervention: Literature summary and patient registry features
Number of subjects: 1016
Study 6827742 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized control trials (RCTs)
Number of subjects: 1016
Study 6827742 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized control trials (RCTs) and patient registries
Number of subjects: 1016
Study 31137756 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical warm-up (WU)
Number of subjects: 11
Study 31137756 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-up complemented with ballistic exercises (PAP)
Number of subjects: 11
Study 31137756 — intervention group
Group type: COMPARATOR
Intervention: No warm-up (NWU)
Number of subjects: 11
Study 30136069 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer Mentors
Number of subjects: 0
Study 30136069 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 26455450 — intervention group
Group type: EXPERIMENTAL
Intervention: XEN-D0103 (3 µM)
Number of subjects: 3
Study 26455450 — intervention group
Group type: EXPERIMENTAL
Intervention: XEN-D0103 (10 µM)
Number of subjects: 3
Study 26455450 — intervention group
Group type: EXPERIMENTAL
Intervention: XEN-D0103
Number of subjects: 3
Study 24501044 — intervention group
Group type: EXPERIMENTAL
Intervention: Activation of mating motives
Number of subjects: 0
Study 22371887 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab plus ABVD (RABVD)
Number of subjects: 85
Study 20350025 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Bereavement Program (FBP)
Number of subjects: 244
Study 20350025 — intervention group
Group type: COMPARATOR
Intervention: Literature control condition
Number of subjects: 244
Study 17537289 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobalamin (1000 microg) plus Folic Acid (400 microg)
Number of subjects: 195
Study 17537289 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobalamin (1000 microg)
Number of subjects: 195
Study 17537289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study 17537289 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobalamin plus Folic Acid
Number of subjects: 195
Study 16286135 — intervention group
Group type: EXPERIMENTAL
Intervention: Benique sound‐Karl Storz
Number of subjects: 0
Study 16286135 — intervention group
Group type: COMPARATOR
Intervention: Traditional sound
Number of subjects: 0
Study 11897434 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum digoxin concentration (0.5 to 0.9 ng/ml)
Number of subjects: 0
Study 11897434 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate serum digoxin concentration (0.9 to 1.2 ng/ml)
Number of subjects: 0
Study 11897434 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum digoxin concentration (>1.2 ng/ml)
Number of subjects: 0
Study 11897434 — intervention group
Group type: COMPARATOR
Intervention: Placebo (digoxin withdrawn)
Number of subjects: 0
Study 10194736 — intervention group
Group type: EXPERIMENTAL
Intervention: Light‐cone technique
Number of subjects: 20
Study 10194736 — intervention group
Group type: COMPARATOR
Intervention: Incremental layering technique
Number of subjects: 20
Study 10194736 — intervention group
Group type: COMPARATOR
Intervention: Curing light transmission into the proximal box
Number of subjects: 20
Study 7762545 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 29
Study 7762545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 7762545 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine and Placebo
Number of subjects: 29
Study 2271507 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenine arabinoside (Ara‐A) 15 mg/Kg, iv, for 10 days
Number of subjects: 40
Study 2271507 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha‐interferon (alpha‐INF) 3 million units, sc, every other day for 12 weeks
Number of subjects: 40
Study 2271507 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 40
Study 2271507 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha‐interferon (alpha‐INF)
Number of subjects: 40